Free Trial

AxoGen (AXGN) Competitors

AxoGen logo
$18.00 -0.50 (-2.70%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$15.76 -2.24 (-12.47%)
As of 02/21/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AXGN vs. WRBY, LIVN, ENOV, NVCR, TMDX, LMAT, TNDM, SLNO, CNMD, and CDRE

Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.

AxoGen vs.

Warby Parker (NYSE:WRBY) and AxoGen (NASDAQ:AXGN) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.

In the previous week, Warby Parker had 5 more articles in the media than AxoGen. MarketBeat recorded 9 mentions for Warby Parker and 4 mentions for AxoGen. AxoGen's average media sentiment score of 0.61 beat Warby Parker's score of 0.49 indicating that AxoGen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Warby Parker
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AxoGen
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Warby Parker has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.

AxoGen has lower revenue, but higher earnings than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Warby Parker$669.77M3.65-$63.20M-$0.27-89.00
AxoGen$159.01M4.98-$21.72M-$0.32-56.25

Warby Parker has a net margin of -4.39% compared to AxoGen's net margin of -7.91%. Warby Parker's return on equity of -8.26% beat AxoGen's return on equity.

Company Net Margins Return on Equity Return on Assets
Warby Parker-4.39% -8.26% -4.37%
AxoGen -7.91%-14.91%-7.49%

93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 26.6% of Warby Parker shares are owned by insiders. Comparatively, 7.0% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

AxoGen received 414 more outperform votes than Warby Parker when rated by MarketBeat users. Likewise, 72.76% of users gave AxoGen an outperform vote while only 42.11% of users gave Warby Parker an outperform vote.

CompanyUnderperformOutperform
Warby ParkerOutperform Votes
40
42.11%
Underperform Votes
55
57.89%
AxoGenOutperform Votes
454
72.76%
Underperform Votes
170
27.24%

Warby Parker presently has a consensus target price of $21.92, indicating a potential downside of 8.76%. AxoGen has a consensus target price of $18.33, indicating a potential upside of 1.85%. Given AxoGen's stronger consensus rating and higher probable upside, analysts clearly believe AxoGen is more favorable than Warby Parker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Warby Parker
1 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50
AxoGen
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Warby Parker beats AxoGen on 10 of the 18 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXGN vs. The Competition

MetricAxoGenElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$814.15M$3.41B$5.82B$9.13B
Dividend YieldN/A1.64%4.75%3.86%
P/E Ratio-56.2516.9226.8119.21
Price / Sales4.9873.23429.0769.52
Price / CashN/A44.0938.0134.83
Price / Book8.113.857.644.62
Net Income-$21.72M$92.00M$3.19B$246.06M
7 Day Performance-0.72%4.49%-2.13%-2.63%
1 Month Performance-3.74%8.30%-1.11%-2.57%
1 Year Performance73.58%14.29%15.71%12.71%

AxoGen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXGN
AxoGen
1.048 of 5 stars
$18.00
-2.7%
$18.33
+1.9%
+76.0%$814.15M$159.01M-56.25450Upcoming Earnings
News Coverage
WRBY
Warby Parker
2.5369 of 5 stars
$25.70
-2.7%
$21.77
-15.3%
+69.9%$2.61B$669.77M-95.193,491Upcoming Earnings
Analyst Forecast
LIVN
LivaNova
3.7044 of 5 stars
$47.68
+0.1%
$69.17
+45.1%
-15.6%$2.59B$1.15B113.522,900Upcoming Earnings
ENOV
Enovis
3.4525 of 5 stars
$43.89
+0.4%
$64.83
+47.7%
-33.0%$2.50B$1.71B-20.046,550Short Interest ↓
Positive News
NVCR
NovoCure
3.4767 of 5 stars
$22.48
+3.5%
$32.67
+45.3%
+44.9%$2.43B$509.34M-16.061,453Upcoming Earnings
News Coverage
TMDX
TransMedics Group
3.6176 of 5 stars
$72.18
+1.3%
$122.70
+70.0%
-15.2%$2.42B$241.62M76.79210News Coverage
Gap Up
LMAT
LeMaitre Vascular
2.0323 of 5 stars
$98.65
+1.7%
$94.63
-4.1%
+64.2%$2.22B$193.48M53.91490Positive News
TNDM
Tandem Diabetes Care
4.0733 of 5 stars
$33.47
+2.6%
$53.81
+60.8%
+24.0%$2.20B$747.72M-17.342,400Upcoming Earnings
Positive News
SLNO
Soleno Therapeutics
4.5359 of 5 stars
$49.17
-4.2%
$71.20
+44.8%
-5.1%$2.12BN/A-14.8130News Coverage
Positive News
CNMD
CONMED
4.6526 of 5 stars
$63.05
-2.1%
$77.20
+22.4%
-25.0%$1.95B$1.31B14.874,000
CDRE
Cadre
2.8965 of 5 stars
$35.14
-1.6%
$39.67
+12.9%
-6.1%$1.43B$482.53M42.342,435

Related Companies and Tools


This page (NASDAQ:AXGN) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners